Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 3Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 23Lymphoma, Non-Hodgkin 18Leukemia, Myeloid, Acute 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lung Neoplasms 15Leukemia 13Carcinoma, Non-Small-Cell Lung 13Burkitt Lymphoma 13Recurrence 9Multiple Myeloma 9Lymphoma, Follicular 8Hodgkin Disease 8Leukemia, Lymphocytic, Chronic, B-Cell 7Congenital Abnormalities 7Lymphoma, B-Cell 6Sarcoma 5Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasms, Plasma Cell 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

Cisplatin 3Pemetrexed 2Etoposide 2pomalidomide 1etoposide phosphate 1enzalutamide 1bemiparin 1apalutamide 1alvocidib 1abiraterone 1Radiation 1RRx-001 1Gemcitabine 1GSK2879552 1Depsipeptides 1Carboplatin 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Small Cell × Etoposide × Clear all
NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡